Magpie Diagnostics
Ovarian

Biomarker & Molecular Overview: Ovarian Cancer

How biomarker and molecular testing guides therapy-class decisions in ovarian.

✓ Medically reviewedApril 4, 20267 min read
Share

Ovarian cancer is not a single disease. Under the umbrella term sit several biologically distinct epithelial histotypes, high-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGSC), clear cell, endometrioid, and mucinous, each with its own molecular signature, natural history, and response to therapy. Molecular and biomarker testing is what turns "ovarian cancer" into an actionable diagnosis. This hub page orients you to the tests that matter, grouped by what they are for: establishing lineage and diagnosis, estimating prognosis, and, increasingly, gating access to specific therapy classes. Each biomarker named below links to its own detail article.

A word on framing: biomarker results connect patients to eligibility for a class of therapy. They do not, by themselves, dictate an individual's treatment plan, which depends on stage, prior therapy, comorbidity, and shared decision-making. The evidence in several areas below is fast-moving, and those areas are flagged explicitly.

Why Molecular Testing Matters Here

Two forces make molecular characterization central in ovarian cancer. First, histotype determines the therapeutic pathway, the chemosensitivity, surgical approach, and drug-class eligibility of a clear cell carcinoma differ fundamentally from those of HGSC, and immunohistochemistry (IHC) is often what distinguishes them [1][15][16]. Second, the arrival of PARP inhibitors transformed the management of homologous-recombination-deficient disease, making DNA-repair biomarkers not descriptive but predictive of benefit [2][3][17][18][19]. Testing therefore does double duty: it refines the diagnosis and it opens (or closes) doors to specific drug classes.

What Gets Tested (Grouped by Purpose)

Diagnostic / Lineage Markers

These IHC-based markers assign histotype, and histotype drives everything downstream.

  • WT1, Nuclear WT1 expression supports a serous lineage (HGSC or LGSC), while WT1-negativity points toward clear cell, endometrioid, or mucinous histotypes [4][11]. WT1 is a workhorse for separating serous from non-serous histotypes and for distinguishing gynaecologic (müllerian) from metastatic gastrointestinal or breast primaries [4][11]. It does not reliably separate ovarian from uterine serous carcinoma: endometrial serous carcinoma is also WT1-positive and can be indistinguishable from ovarian high-grade serous carcinoma by immunohistochemistry alone [12].

  • p53 (aberrant pattern), By IHC, p53 is a surrogate for TP53 mutation status. An aberrant pattern, either diffuse strong overexpression or complete absence (null), supports HGSC, whereas a wild-type (heterogeneous, moderate) pattern in a WT1-positive tumor supports LGSC [1][5][12][13]. Because TP53 alteration is a near-defining molecular feature of HGSC [5][13], this single stain can pivot the entire treatment approach, LGSC and HGSC are managed differently.

  • Napsin A / HNF1-beta, These markers support a clear cell histotype. The classic clear cell profile is WT1-negative, p53 wild-type, and Napsin A, positive [1][6][14]. Recognizing clear cell carcinoma matters because it is relatively chemo-resistant and managed distinctly from serous disease [6][15].

Prognostic Markers

Histotype itself carries prognostic weight, so the lineage markers above are also prognostically informative. Clear cell histotype (Napsin A / HNF1-beta positive) flags a tumor with different chemosensitivity [6][15][16], and the p53/WT1 combination that separates LGSC from HGSC carries different implications for tempo and outcome [5][16]. In this sense several markers straddle the diagnostic and prognostic categories.

Predictive / Therapy-Gating Markers

  • BRCA1/2 (germline and somatic), Pathogenic BRCA1/2 alterations, whether inherited (germline, tested from blood) or arising within the tumor (somatic, tested from FFPE tissue by NGS), are the anchor predictive biomarker in epithelial ovarian cancer. Their presence gates PARP-inhibitor therapy, both as maintenance and as treatment, in high-grade serous/epithelial disease [2][3]. Germline testing additionally informs risk-reducing surgery and cascade testing of relatives [3][20][21].

  • Homologous recombination deficiency (HRD), HRD extends the biology of BRCA beyond the two genes. Composite genomic-scar assays (loss of heterozygosity, telomeric allelic imbalance, large-scale state transitions) combined with BRCA status classify a tumor as HRD-positive or HRD-negative [7][8]. HRD-positive status broadens the population predicted to benefit from PARP-inhibitor therapy beyond BRCA-mutant cases alone, particularly in the maintenance setting and in combination with bevacizumab [7][8][17][18][19].

  • Mismatch repair / MSI (dMMR), MMR-protein loss by IHC or microsatellite instability by PCR/NGS is most relevant in endometrioid and clear cell histotypes [1][9][22]. A dMMR/MSI-high result serves two purposes: it identifies candidates for Lynch syndrome evaluation, and it gates tumor-agnostic checkpoint-inhibitor (immunotherapy) eligibility [9][23].

  • HER2 (in mucinous histotype), In the mucinous subset, HER2 overexpression or amplification (by IHC and ISH) identifies tumors that may be candidates for HER2-directed therapy [1][10]. This is an emerging/trial-context linkage rather than an established standard, and it applies to a narrow histotype-defined population [10][23].

How Results Steer Treatment (Result → Drug Class)

  • BRCA-mutant (germline or somatic) → eligibility for PARP-inhibitor therapy [2][3].
  • HRD-positive → broadened PARP-inhibitor eligibility, including with anti-angiogenic (bevacizumab) maintenance [7][8][17][18][19].
  • dMMR / MSI-high → checkpoint-inhibitor immunotherapy eligibility under tumor-agnostic indications [9][22][23].
  • HER2-positive mucinous carcinoma → potential HER2-directed approaches, largely in trial settings [10].
  • Histotype assignment (via WT1, p53, Napsin A/HNF1-beta) → selection of the histotype-appropriate chemotherapy/management pathway [1][4][5][6][11][15][16].

Specimen and Testing Realities

Testing draws on two specimen streams. Germline BRCA1/2 analysis uses blood (or another normal-tissue source) and speaks to heritable risk and cascade testing [3][23]. Somatic analysis, tumor NGS for BRCA1/2, HRD genomic-scar scoring, and MSI, uses formalin-fixed paraffin-embedded (FFPE) tissue [2][7]. Because germline and somatic testing answer different questions, complete workup often requires both.

The diagnostic IHC panel (WT1, p53, Napsin A/HNF1-beta, MMR proteins) is FFPE-based and frequently deployed as reflex testing once a suspicious specimen is received, so that histotype and dMMR status are established early [1][12]. dMMR screening by IHC can trigger reflex MSI confirmation and germline referral [9][23].

Liquid biopsy (circulating tumor DNA) is an area of active development for detecting somatic BRCA and other alterations when tissue is limited, but tissue remains the reference specimen for HRD scoring and histotyping [24][25]. This is a fast-moving space, and practice is still consolidating.

What's Emerging

Several areas warrant explicit caution as evolving. HRD assay standardization is unsettled, different genomic-scar platforms use different thresholds, and the boundary of who benefits beyond BRCA continues to be refined in maintenance trials [7][8][17][18][19]. HER2-directed therapy in mucinous ovarian carcinoma rests on a small histotype-defined subset and remains largely investigational [10]. Checkpoint-inhibitor benefit in ovarian cancer is most defensible in the dMMR/MSI-high context; broader immunotherapy application remains under study [9][22]. The evidence suggests these domains will shift as trial data mature, and results should be interpreted with that provisionality in mind.

References

  1. WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed. IARC, Lyon; 2020. ISBN 978-92-832-4504-9.
  2. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (SOLO-1). N Engl J Med; 2018. PMID: 30345884.
  3. Armstrong DK, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol; 2022. PMCID: PMC8942301.
  4. Al-Hussaini M, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. 2004. PMID: 14764054.
  5. Kuhn E, et al. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma. J Pathol; 2016. PMCID: PMC4696053.
  6. Ordóñez NG. Napsin A as a marker of clear cell ovarian carcinoma. Int J Gynecol Pathol; 2014. PMCID: PMC4228360.
  7. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (PAOLA-1). N Engl J Med; 2019. PMID: 31851799. González-Martín A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (PRIMA). N Engl J Med; 2019. PMID: 31562799.
  8. Homologous Recombination Deficiency in Ovarian Cancer. PMCID: PMC9968181.
  9. Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors. PMCID: PMC12072705.
  10. McAlpine JN, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer; 2009. PMCID: PMC2803495.
  11. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol; 2010. PMID: 19967725.
  12. McCluggage WG, Judge MJ, Clarke BA, et al. Data set for reporting of ovarian, fallopian tube and primary peritoneal carcinoma (ICCR). Mod Pathol; 2015. PMID: 26089092.
  13. Köbel M, Piskorz AM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res; 2016. PMID: 27840695.
  14. Li Q, et al. Dual HNF-1β and napsin A immunohistochemistry in the diagnosis of ovarian clear cell carcinoma. Int J Clin Exp Pathol; 2015;8(7):8305-8310.
  15. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer (GCIG). Int J Gynecol Cancer; 2010. PMID: 20683400.
  16. Peres LC, Cushing-Haugen KL, Köbel M, et al. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. J Natl Cancer Inst; 2019. PMID: 29718305.
  17. Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival (PAOLA-1/ENGOT-ov25). Ann Oncol; 2023. PMID: 37211045.
  18. Monk BJ, Parkinson C, Lim MC, et al. A Randomized, Phase III Trial of Maintenance Rucaparib in Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol; 2022. PMID: 35658487.
  19. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3). Lancet; 2017. PMID: 28916367.
  20. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst; 2009. PMID: 19141781.
  21. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol; 2008. PMID: 18268356.
  22. Rambau PF, Duggan MA, Ghatage P, et al. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. Histopathology; 2016. PMID: 26799366.
  23. National Complete Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Ovarian Cancer (notes on germline/somatic testing, reflex MMR-IHC, and tumor-agnostic checkpoint eligibility).
  24. Hou JY, Chapman JS, Kalashnikova E, et al. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecol Oncol; 2022. PMID: 36117009.
  25. Taliento C, et al. Circulating tumor DNA in the diagnosis of ovarian cancer: a systematic review. Int J Gynecol Cancer; 2026. PMID: 41136311.

Tags

biomarkersmolecular testing